BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38244844)

  • 1. ATP-adenosine axis regulation combined with microneedle assisted photoimmunotherapy to boost the immunotherapy efficiency.
    Shi C; Chen M; Li X; Fu Y; Yang D; Wen T; Zhao W; Sun Y; Wang W; Lu C; Wu Q; Wu C; Pan X; Quan G
    J Control Release; 2024 Mar; 367():1-12. PubMed ID: 38244844
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Chen M; Yang D; Sun Y; Liu T; Wang W; Fu J; Wang Q; Bai X; Quan G; Pan X; Wu C
    ACS Nano; 2021 Feb; 15(2):3387-3401. PubMed ID: 33576607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiating dual-directional immunometabolic regulation with nanomedicine to enhance anti-tumor immunotherapy following incomplete photothermal ablation.
    Jiang Q; Qiao B; Zheng J; Song W; Zhang N; Xu J; Liu J; Zhong Y; Zhang Q; Liu W; You L; Wu N; Liu Y; Li P; Ran H; Wang Z; Guo D
    J Nanobiotechnology; 2024 Jun; 22(1):364. PubMed ID: 38915007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.
    Ogawa M; Tomita Y; Nakamura Y; Lee MJ; Lee S; Tomita S; Nagaya T; Sato K; Yamauchi T; Iwai H; Kumar A; Haystead T; Shroff H; Choyke PL; Trepel JB; Kobayashi H
    Oncotarget; 2017 Feb; 8(6):10425-10436. PubMed ID: 28060726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of oxaliplatin and POM-1 by nanoliposomes to reprogram the tumor immune microenvironment.
    Fu X; Shi Y; Zang H; Wang Q; Wang Y; Wu H; Qiu S; Shen H; Mo F; Zhang Y; Lin G
    J Control Release; 2022 Jul; 347():1-13. PubMed ID: 35508221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
    Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cold to Hot: Binary Cooperative Microneedle Array-Amplified Photoimmunotherapy for Eliciting Antitumor Immunity and the Abscopal Effect.
    Chen M; Quan G; Wen T; Yang P; Qin W; Mai H; Sun Y; Lu C; Pan X; Wu C
    ACS Appl Mater Interfaces; 2020 Jul; 12(29):32259-32269. PubMed ID: 32406239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
    Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
    Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
    Bao X; Xie L
    J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression.
    Mao C; Yeh S; Fu J; Porosnicu M; Thomas A; Kucera GL; Votanopoulos KI; Tian S; Ming X
    Sci Transl Med; 2022 Jun; 14(648):eabh1261. PubMed ID: 35675434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma.
    Sun T; Li Y; Yang Y; Liu B; Cao Y; Yang W
    Cell Death Dis; 2022 Oct; 13(10):875. PubMed ID: 36245000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model.
    Hsu MA; Okamura SM; De Magalhaes Filho CD; Bergeron DM; Rodriguez A; West M; Yadav D; Heim R; Fong JJ; Garcia-Guzman M
    Cancer Immunol Immunother; 2023 Jan; 72(1):151-168. PubMed ID: 35776159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-Assembled Immunostimulatory Tetrahedral Framework Nucleic Acid Vehicles for Tumor Chemo-immunotherapy.
    Liu M; Hao L; Zhao D; Li J; Lin Y
    ACS Appl Mater Interfaces; 2022 Aug; 14(34):38506-38514. PubMed ID: 35973112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD39 - A bright target for cancer immunotherapy.
    Guo S; Han F; Zhu W
    Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinational phototherapy and hypoxia-activated chemotherapy favoring antitumor immune responses.
    Ma B; Sheng J; Wang P; Jiang Z; Borrathybay E
    Int J Nanomedicine; 2019; 14():4541-4558. PubMed ID: 31417257
    [No Abstract]   [Full Text] [Related]  

  • 18. Dissolving microneedles-based programmed delivery system for enhanced chemo-immunotherapy of melanoma.
    Tian Y; Jing H; Wang Q; Hu S; Wu Z; Duan Y
    J Control Release; 2023 Aug; 360():630-646. PubMed ID: 37414221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-Responsive Smart Hydrogel Releasing Immune Adjuvant Synchronized with Repeated Chemotherapy or Radiotherapy to Boost Antitumor Immunity.
    Sun L; Shen F; Tian L; Tao H; Xiong Z; Xu J; Liu Z
    Adv Mater; 2021 May; 33(18):e2007910. PubMed ID: 33788339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.